Life cycle management (LCM) is an expression that conjures up thoughts of price increases, “evergreening” and patent litigation – all of which carry negative connotations. But LCM is a fundamental part of every successful drug, with many separate strategies underpinning the growth profiles and longevity of the industry’s top-selling drugs.
Pipeline-in-a-pill is one such strategy, clearly evident with the 10 indications of Humira (adalimumab), or 100-plus pages that constitute Keytruda’s...



